Skip to Main Content

Biogen’s sales and profit will decline this year, but the commercial launches of an Alzheimer’s treatment and a new medicine for depression are expected to help the company return to growth, newly appointed CEO Chris Viehbacher said Wednesday.

Stelios Papadopoulos, the longtime chairman of Biogen’s board, will also be stepping down this year due to the company’s mandatory retirement age policy, Viehbacher said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment